# OnCo record racotumomab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/racotumomab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "racotumomab" ;
  schema:name "Racotumomab"@en ;
  schema:alternateName "Racotumomab-alum"@en, "Vaxira" ;
  schema:description "Racotumomab (Vaxira) is a Cuban vaccine for advanced non-small cell lung cancer, given after first-line treatment to patients whose cancer has responded or held steady. In a placebo-controlled trial of 176 patients it lengthened median survival from 6.8 to 8.2 months. It is registered in Cuba and is not approved in the United States or the European Union."@en ;
  schema:url <https://onco.cc/drugs/racotumomab/> ;
  schema:dateModified "2026-11-16"^^xsd:date ;
  schema:citation <https://www.cecmed.cu/registro/rcp/biologicos/vaxirar-racotumomab>, <https://doi.org/10.1158/1078-0432.CCR-13-1674> ;
  onco:status "established" ;
  onco:tag "cuba", "cancer-vaccine" ;
  onco:modality "Therapeutic cancer vaccine: anti-idiotype monoclonal antibody adsorbed on aluminium hydroxide, intradermal" ;
  onco:approval "Cuba (CECMED) 2025: Advanced (stage IIIB or IV) non-small cell lung cancer with an objective response or stable disease after first-line treatment (switch maintenance)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:companies <https://onco.cc/companies/cimab/> ;
  onco:institutions <https://onco.cc/institutions/cecmed/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-alfonso-racotumomab-maintenance-nsclc-ccr-2014/> .
